2020-03-29
Researchers from the University of Helsinki in collaboration with Cour Pharmaceutical Development Company, Inc., an American biopharmaceutical company that designs therapies to reprogram the immune system for achieving antigen-specific tolerance in immune-mediated diseases, have jointly developed special nanoparticles containing gliadin for the immunomodulatory treatment of celiac disease,...
